Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K102189
    Date Cleared
    2012-03-14

    (590 days)

    Product Code
    Regulation Number
    880.6250
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Powder Free Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs Labeling Claim is a specialty medical glove which is a disposable device intended for medical purpose that is worn on the examiner's hand or finger to prevent contamination between examiner and patient. In addition these gloves are worn to protect the wearer against exposure to chemotherapy drugs. Tested chemotherapy drugs are as follows:
    Cisplatin, 1.0 mg/ml ≥ 240
    Cyclophosphamide (Cytoxan), 20.0 mg/ml ≥ 240
    Cytarabine, 100 mg/ml ≥ 240
    Cytovene, 10 mg/ml ≥ 240
    Dacarbazine (DTIC), 10.0 mg/ml ≥ 240
    Docetaxel, 10.0 mg/ml ≥ 240
    Doxorubicin Hydrochloride, 2.0 mg/ml ≥ 240
    Etoposide (Toposar), 20.0 mg/ml ≥ 240
    Fluorouracil, 50.0 mg/ml ≥ 240
    Ifosfamide, 50.0 mg/ml ≥ 240
    Irinotecan Hydrochloride, 20 mg/ml ≥ 240
    Mechlorethamine HCI, 1.0 mg/ml ≥ 240
    Methotrexate, 25 mg/ml ≥ 240
    Mitomycin C, 0.5 mg/ml ≥ 240
    Mitoxantrone, 2 mg/ml ≥ 240
    Oxaliplatin, 5mg/ml ≥ 240
    Paclitaxel (Taxol), 6.0 mg/ml ≥ 240
    ThioTEPA 75.8
    Vincristine Sulfate, 1.0 mg/ml ≥ 240
    Vinorelbine, 10 mg/ml ≥ 240
    Low Permeation Time (minutes) 1.7
    Carmustine (BCNU), 3.3 mg/ml
    Please note that the following drug has an extremely low permeation time: Carmustine (BCNU) 1.7 (mins)

    Device Description

    Powder-Free Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs Labeling Claim, meeting all the requirements of ASTM standards D6319-10 and ASTM D6124-06. The gloves are non-sterile, single-use, disposable devices.

    AI/ML Overview

    The provided text is a 510(k) summary for "Powder-Free Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs Labeling Claim." This document describes the device's characteristics and performance to demonstrate substantial equivalence to a predicate device. It is not an AI/ML device, and therefore several of the requested sections (e.g., sample size for test set, number of experts, adjudication method, MRMC study, standalone performance, training set size) are not applicable.

    Here's the information that can be extracted:


    Acceptance Criteria and Device Performance Study for Powder-Free Nitrile Examination Gloves

    This device is not an AI/ML device, and thus many of the requested sections related to AI/ML study design are not applicable. The device is a physical medical glove.

    1. Table of Acceptance Criteria and Reported Device Performance

    CharacteristicStandard/Acceptance CriteriaDevice Performance
    DimensionsASTM D6319-10Meets standard requirements
    Physical PropertiesASTM D6319-10Meets standard requirements
    ThicknessASTM D6319-10Meets standard requirements (Palm Thickness: ≥0.10 mm; Finger Thickness: ≥0.10 mm; Length: ≥270 mm)
    BiocompatibilityPrimary Skin Irritation Study (ISO 10993-0:2002E); Dermal Sensitization (ASTM-F 720-81)Passes (Not a primary skin irritant); Passes (Not a contact sensitizer)
    Watertight - 1000 ml (Freedom from Holes)21 CFR 800.20 (AQL 2.5 required per standard)Passes (Gloves Free of Holes at quality level of AQL 1.5, which is better than required)
    Resistance to Permeation by Chemotherapy DrugsASTM D6978-05 (Specific breakthrough times for various drugs)Meets standard requirements for most drugs: - Cisplatin, 1.0 mg/ml: ≥ 240 minutes - Cyclophosphamide (Cytoxan), 20.0 mg/ml: ≥ 240 minutes - Cytarabine, 100 mg/ml: ≥ 240 minutes - Cytovene, 10 mg/ml: ≥ 240 minutes - Dacarbazine (DTIC), 10.0 mg/ml: ≥ 240 minutes - Docetaxel, 10.0 mg/ml: ≥ 240 minutes - Doxorubicin Hydrochloride, 2.0 mg/ml: ≥ 240 minutes - Etoposide (Toposar), 20.0 mg/ml: ≥ 240 minutes - Fluorouracil, 50.0 mg/ml: ≥ 240 minutes - Ifosfamide, 50.0 mg/ml: ≥ 240 minutes - Irinotecan Hydrochloride, 20 mg/ml: ≥ 240 minutes - Mechlorethamine HCl, 1.0 mg/ml: ≥ 240 minutes - Methotrexate, 25 mg/ml: ≥ 240 minutes - Mitomycin C, 0.5 mg/ml: ≥ 240 minutes - Mitoxantrone, 2 mg/ml: ≥ 240 minutes - Oxaliplatin, 5mg/ml: ≥ 240 minutes - Paclitaxel (Taxol), 6.0 mg/ml: ≥ 240 minutes - Vincristine Sulfate, 1.0 mg/ml: ≥ 240 minutes - Vinorelbine, 10 mg/ml: ≥ 240 minutes Exceptions: - ThioTEPA: 75.8 minutes - Carmustine (BCNU), 3.3 mg/ml: 1.7 minutes (noted as extremely low permeation time)
    Design Specifications & Glove PerformanceASTM D6319-10 (Tensile Strength ≥ 14MPa; Elongation ≥400%)Meets ASTM D6319-10 (Tensile Strength ≥ 14MPa; Elongation ≥400%)
    MaterialsN/A (Compared to predicate)Flexible Nitrile
    ColorN/A (Compared to predicate)Synthetic Glove with embedded BLUE Biocompatible Colorant
    Technology of Glove Design (Coatings/Donning Aid)N/A (Compared to predicate)Ambidextrous; Inner Glove Surface Chlorine Treated to Facilitate Donning; Fingertips Textured to Improve Tactility and Grip
    Powder-FreeApplicable Definition for Powder Free (< 2 mg per glove)Meets Applicable Definition for Powder Free; < 2 mg per glove
    SterilityNot Applicable (Non-Sterile)Not Applicable: Non-Sterile

    2. Sample Size Used for the Test Set and Data Provenance

    The document does not explicitly state the sample sizes for the individual tests (e.g., number of gloves tested for each characteristic or drug permeation). The tests were performance-based, carried out according to ASTM standards for physical device properties and chemical resistance.

    • Data Provenance: The tests were conducted by Latexx Manufacturing Sdn. Bhd., located in Malaysia. The document doesn't specify if the data itself originated from Malaysia or another country, but the manufacturing site is in Malaysia. The studies are retrospective from the perspective of being submitted for regulatory approval, as they were completed prior to the submission.

    3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications

    N/A. This is a physical device, and the "ground truth" is established by performance against pre-defined standardized physical and chemical tests (e.g., ASTM standards for tensile strength, elongation, dimensions, and chemotherapy drug permeation), not by expert interpretation of data.

    4. Adjudication Method for the Test Set

    N/A. Not applicable for a physical device undergoing standardized mechanical and chemical testing.

    5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study was done

    N/A. This is not an AI/ML diagnostic device; it is a physical medical glove.

    6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done

    N/A. This is not an AI/ML device. The tests performed are inherent to the material properties and design of the glove.

    7. The Type of Ground Truth Used

    The "ground truth" for the device's performance is established by standardized laboratory testing procedures defined by international and national standards (e.g., ASTM D6319-10, ASTM D6124-06, ASTM D6978-05, ISO 10993-0:2002E, ASTM-F 720-81, 21 CFR 800.20). These standards define the methodology for measuring characteristics like dimensions, physical properties, biocompatibility, watertight integrity, and resistance to chemotherapy drug permeation.

    8. The Sample Size for the Training Set

    N/A. This is a physical device, not an AI/ML algorithm that requires a training set. The device itself is manufactured, and its performance is tested against standards.

    9. How the Ground Truth for the Training Set Was Established

    N/A. Not applicable for a physical device.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1